Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of FDC Ketoprofen + Omeprazole in Rheumatological Conditions
NCT00971581Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ketoprofen and omeprazole in rheumatoid arthritis (RA), ankylosing spondylitis (AS), reactive arthritis and 1 more, sponsored by Sanofi. Primary endpoints: To confirm the efficacy of the combination and Incidence of dyspeptic symptoms: epigastric pain, dyspepsia, nausea at Day 10. Started Aug 2009; status: completed.
02
Drugs
ketoprofenomeprazole
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)reactive arthritispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00971581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00971581.